# ![@MetseraInc Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1852033473810227200.png) @MetseraInc Metsera Inc.

Metsera Inc. posts on X about we are, ceo, financial, future the most. They currently have [-------] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: [--] [#](/creator/twitter::1852033473810227200/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1852033473810227200/c:line/m:interactions.svg)

- [--] Week [--] -29%
- [--] Months [---] -20%

### Mentions: [--] [#](/creator/twitter::1852033473810227200/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1852033473810227200/c:line/m:posts_active.svg)


### Followers: [-------] [#](/creator/twitter::1852033473810227200/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1852033473810227200/c:line/m:followers.svg)

- [--] Months [---] +90%

### CreatorRank: undefined [#](/creator/twitter::1852033473810227200/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1852033473810227200/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [finance](/list/finance)  [exchanges](/list/exchanges)  [travel destinations](/list/travel-destinations) 

**Social topic influence**
[we are](/topic/we-are), [ceo](/topic/ceo), [financial](/topic/financial), [future](/topic/future), [reduce](/topic/reduce), [weight loss](/topic/weight-loss), [portfolio of](/topic/portfolio-of), [watch](/topic/watch), [thank you](/topic/thank-you), [we will](/topic/we-will)

**Top accounts mentioned or mentioned by**
[@bradloncar](/creator/undefined) [@biotechtvhq](/creator/undefined) [@nasdaqexchange](/creator/undefined) [@nasdaq](/creator/undefined) [@pfizer](/creator/undefined) [@pfizernews](/creator/undefined) [@pfizer_news](/creator/undefined)

**Top assets mentioned**
[Metsera, Inc. (MTSR)](/topic/$mtsr)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Today we announced the positive topline results from the Phase 2a clinical trial of MET-097i our ultra-long acting GLP-1 receptor agonist. Full release available here: https://www.businesswire.com/news/home/20250106419531/en/Metsera-Announces-Positive-Topline-Phase-2a-Clinical-Data-for-its-Ultra-Long-Acting-GLP-1-Receptor-Agonist-MET-097i https://www.businesswire.com/news/home/20250106419531/en/Metsera-Announces-Positive-Topline-Phase-2a-Clinical-Data-for-its-Ultra-Long-Acting-GLP-1-Receptor-Agonist-MET-097i"  
[X Link](https://x.com/MetseraInc/status/1876601006609375535)  2025-01-07T12:05Z [---] followers, [---] engagements


"Obesity impacts over a billion people worldwide leading to significant physical emotional and economic burdens on individuals and society. At Metsera our purpose is to reduce these burdens by developing trusted convenient and accessible medicines. This #WorldObesityDay we recognize the urgent need for scaled solutions for people with obesity. https://twitter.com/i/web/status/1896929549092364469 https://twitter.com/i/web/status/1896929549092364469"  
[X Link](https://x.com/anyuser/status/1896929549092364469)  2025-03-04T14:23Z [---] followers, [---] engagements


"An excitingday for Metsera as we celebrate our official listing on @NasdaqExchange as $MTSR This marks an important step for the company and we extend thanks to our team and partners for their support in achieving this milestone"  
[X Link](https://x.com/anyuser/status/1885435968255131738)  2025-01-31T21:12Z [---] followers, [---] engagements


"This morning we announced our fourth quarter and full year [----] financial results and continued portfolio progress on our lead program MET-097i as well as our earlier-stage product candidates. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-fourth-quarter-and-full-year-2024-financial https://investors.metsera.com/news-releases/news-release-details/metsera-reports-fourth-quarter-and-full-year-2024-financial"  
[X Link](https://x.com/anyuser/status/1904852957671174244)  2025-03-26T11:08Z [---] followers, [----] engagements


"Metsera CEO Whit Bernard recently joined @bradloncar on @BiotechTVHQ to talk about what sets Metsera apart. Whit shares how were advancing a broad portfolio of therapies with potential best-in-class profiles to meet the future needs of a rapidly evolving weight loss treatment landscape. Watch the full conversation to learn more about how were accelerating the next generation of medicines for obesity and metabolic diseases: https://www.biotechtv.com/post/metsera-april-23-2025 https://www.biotechtv.com/post/metsera-april-23-2025"  
[X Link](https://x.com/anyuser/status/1915762138842382822)  2025-04-25T13:37Z [---] followers, [---] engagements


"This morning we rang the @Nasdaq #OpeningBell in celebration of $MTSRs listing. It was a proud & symbolic moment for us highlighting the dedication of our team & our continued focus on addressing the burden of #obesity with trusted accessible medicines. Thank you to our exceptional team partners & supporters who helped make this day possible. https://twitter.com/i/web/status/1920203804890591350 https://twitter.com/i/web/status/1920203804890591350"  
[X Link](https://x.com/anyuser/status/1920203804890591350)  2025-05-07T19:47Z [---] followers, [---] engagements


"Today we reported our first quarter [----] financial results and continued portfolio progress. We remain on track to deliver on all of our committed clinical milestones for [----]. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-first-quarter-2025-financial-results-and https://investors.metsera.com/news-releases/news-release-details/metsera-reports-first-quarter-2025-financial-results-and"  
[X Link](https://x.com/anyuser/status/1921884354562638291)  2025-05-12T11:05Z [---] followers, [---] engagements


"We are excited toattendthe 85th #ADASciSessions in Chicagoon June [--] - [--]. We will highlight the breadth and momentum of our portfolioof ultra-long acting scalable and combinable therapies including updated clinical and preclinical findings from lead program MET-097i. Details of the presentations can be found here: https://investors.metsera.com/news-releases/news-release-details/metsera-present-new-research-highlighting-breadth-and-momentum https://investors.metsera.com/news-releases/news-release-details/metsera-present-new-research-highlighting-breadth-and-momentum"  
[X Link](https://x.com/anyuser/status/1930596224987496518)  2025-06-05T12:03Z [---] followers, [---] engagements


"We are pleased to share positive Phase [--] data of first-in-class once-monthly amylin candidate MET-233i which was engineered for class-leading durability potency and combinability with Metsera's fully-biased monthly GLP-1 RA candidate MET-097i. MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day [--] a 19-day observed half-life supporting monthly dosing and a favorable tolerability profile with no safety signals. For more details read the full press release here:"  
[X Link](https://x.com/anyuser/status/1932035745994195306)  2025-06-09T11:23Z [---] followers, [----] engagements


"Metsera CEO Whit Bernard will present at theGoldmanSachs 46th Annual Global Healthcare Conferenceon June [--] at 10:00 - 10:35 A.M. ET. To access the live webcast http://investors.metsera.com http://investors.metsera.com"  
[X Link](https://x.com/anyuser/status/1932400983159492938)  2025-06-10T11:34Z [---] followers, [---] engagements


"Metsera CEO Whit Bernard sat down with@BradLoncar at@BiotechTVHQ to discuss whats next in obesity care & how were helping shape that future. Whit shares updates on our pipeline including highlights from ADA & why we believe oral peptides with injectable-like performance can scale to meet the needs of the growing obesity market. Watch the full interview: https://www.biotechtv.com/post/metsera-july-22-2025 https://www.biotechtv.com/post/metsera-july-22-2025"  
[X Link](https://x.com/anyuser/status/1948152954189443101)  2025-07-23T22:47Z [---] followers, [---] engagements


"Today we reported our second quarter [----] financial results and continued portfolio progress.Notably we are on track towards all upcoming clinical milestones including a Phase 2bVESPER-1 and interim VESPER-3 readout of MET-097i in September followedby a planned global Phase [--] initiation of MET-097i in late [----]. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-second-quarter-2025-financial-results-and"  
[X Link](https://x.com/anyuser/status/1949928139016327177)  2025-07-28T20:21Z [---] followers, [---] engagements


"Metsera CEO Whit Bernard will present at the following investor conferences next week: 🔸 Cantor Global Healthcare Conference [----] on September [--] [----] at 3:20-3:50 pm ET. 🔸 Wells Fargo [----] Healthcare Conference on September [--] [----] at 4:30-5:05 pm ET. To access the live webcasts visit http://investors.metsera.com http://investors.metsera.com"  
[X Link](https://x.com/anyuser/status/1960803255170236718)  2025-08-27T20:35Z [---] followers, [---] engagements


"We are excited to attend #EASD2025 in Vienna on September 15-19. We will present clinical and preclinical data from our portfolio of next-generation ultra-long acting scalable and combinable therapies including a late-breaker on the initial efficacy observed for our amylin analog MET-233i. Details of the presentations can be found here: https://investors.metsera.com/news-releases/news-release-details/metsera-present-research-highlighting-its-next-generation https://investors.metsera.com/news-releases/news-release-details/metsera-present-research-highlighting-its-next-generation"  
[X Link](https://x.com/anyuser/status/1966099038576537938)  2025-09-11T11:18Z [---] followers, [---] engagements


"Today we announced that Metsera has entered into an agreement to be acquired by Pfizer. With our portfolioof differentiated oral and injectable nutrient-stimulated hormone therapeutic candidates we believePfizer's global capabilities will help accelerate our purpose to reduce the physical emotional and economic burdens of obesity and related diseases. We are deeply grateful to all who havecontributed to making this milestone possible. For more details read the full announcement here:"  
[X Link](https://x.com/anyuser/status/1970081694993530960)  2025-09-22T11:04Z [---] followers, [----] engagements


"Today we announced positive topline data from VESPER-1 and positive data from a planned interim analysis of VESPER-3 two phase 2b trials of MET-097i.The favorable data in both trials support the advancement of MET-097i into Phase [--] clinical trials & accelerate its development as the foundational peptide for Metsera's combination oral and prodrug programs. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-positive-phase-2b-results-first-and-best-class"  
[X Link](https://x.com/anyuser/status/1972757120744374424)  2025-09-29T20:15Z [---] followers, [----] engagements


"Metsera is now part of Pfizer Thank you for being a follower and please consider following us @Pfizer and @Pfizer_news for future updates. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera"  
[X Link](https://x.com/anyuser/status/1989030612393451969)  2025-11-13T18:00Z [---] followers, [---] engagements


"Metsera is now part of Pfizer Thank you for being a follower and please consider following us @Pfizer and @Pfizer_news for future updates. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera"  
[X Link](https://x.com/anyuser/status/1989030612393451969)  2025-11-13T18:00Z [---] followers, [---] engagements


"Today we announced positive topline data from VESPER-1 and positive data from a planned interim analysis of VESPER-3 two phase 2b trials of MET-097i.The favorable data in both trials support the advancement of MET-097i into Phase [--] clinical trials & accelerate its development as the foundational peptide for Metsera's combination oral and prodrug programs. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-positive-phase-2b-results-first-and-best-class"  
[X Link](https://x.com/anyuser/status/1972757120744374424)  2025-09-29T20:15Z [---] followers, [----] engagements


"Today we announced that Metsera has entered into an agreement to be acquired by Pfizer. With our portfolioof differentiated oral and injectable nutrient-stimulated hormone therapeutic candidates we believePfizer's global capabilities will help accelerate our purpose to reduce the physical emotional and economic burdens of obesity and related diseases. We are deeply grateful to all who havecontributed to making this milestone possible. For more details read the full announcement here:"  
[X Link](https://x.com/anyuser/status/1970081694993530960)  2025-09-22T11:04Z [---] followers, [----] engagements


"We are excited to attend #EASD2025 in Vienna on September 15-19. We will present clinical and preclinical data from our portfolio of next-generation ultra-long acting scalable and combinable therapies including a late-breaker on the initial efficacy observed for our amylin analog MET-233i. Details of the presentations can be found here: https://investors.metsera.com/news-releases/news-release-details/metsera-present-research-highlighting-its-next-generation https://investors.metsera.com/news-releases/news-release-details/metsera-present-research-highlighting-its-next-generation"  
[X Link](https://x.com/anyuser/status/1966099038576537938)  2025-09-11T11:18Z [---] followers, [---] engagements


"Metsera CEO Whit Bernard will present at the following investor conferences next week: 🔸 Cantor Global Healthcare Conference [----] on September [--] [----] at 3:20-3:50 pm ET. 🔸 Wells Fargo [----] Healthcare Conference on September [--] [----] at 4:30-5:05 pm ET. To access the live webcasts visit http://investors.metsera.com http://investors.metsera.com"  
[X Link](https://x.com/anyuser/status/1960803255170236718)  2025-08-27T20:35Z [---] followers, [---] engagements


"Today we reported our second quarter [----] financial results and continued portfolio progress.Notably we are on track towards all upcoming clinical milestones including a Phase 2bVESPER-1 and interim VESPER-3 readout of MET-097i in September followedby a planned global Phase [--] initiation of MET-097i in late [----]. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-second-quarter-2025-financial-results-and"  
[X Link](https://x.com/anyuser/status/1949928139016327177)  2025-07-28T20:21Z [---] followers, [---] engagements


"Metsera CEO Whit Bernard sat down with@BradLoncar at@BiotechTVHQ to discuss whats next in obesity care & how were helping shape that future. Whit shares updates on our pipeline including highlights from ADA & why we believe oral peptides with injectable-like performance can scale to meet the needs of the growing obesity market. Watch the full interview: https://www.biotechtv.com/post/metsera-july-22-2025 https://www.biotechtv.com/post/metsera-july-22-2025"  
[X Link](https://x.com/anyuser/status/1948152954189443101)  2025-07-23T22:47Z [---] followers, [---] engagements


"Metsera CEO Whit Bernard will present at theGoldmanSachs 46th Annual Global Healthcare Conferenceon June [--] at 10:00 - 10:35 A.M. ET. To access the live webcast http://investors.metsera.com http://investors.metsera.com"  
[X Link](https://x.com/anyuser/status/1932400983159492938)  2025-06-10T11:34Z [---] followers, [---] engagements


"We are pleased to share positive Phase [--] data of first-in-class once-monthly amylin candidate MET-233i which was engineered for class-leading durability potency and combinability with Metsera's fully-biased monthly GLP-1 RA candidate MET-097i. MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day [--] a 19-day observed half-life supporting monthly dosing and a favorable tolerability profile with no safety signals. For more details read the full press release here:"  
[X Link](https://x.com/anyuser/status/1932035745994195306)  2025-06-09T11:23Z [---] followers, [----] engagements


"We are excited toattendthe 85th #ADASciSessions in Chicagoon June [--] - [--]. We will highlight the breadth and momentum of our portfolioof ultra-long acting scalable and combinable therapies including updated clinical and preclinical findings from lead program MET-097i. Details of the presentations can be found here: https://investors.metsera.com/news-releases/news-release-details/metsera-present-new-research-highlighting-breadth-and-momentum https://investors.metsera.com/news-releases/news-release-details/metsera-present-new-research-highlighting-breadth-and-momentum"  
[X Link](https://x.com/anyuser/status/1930596224987496518)  2025-06-05T12:03Z [---] followers, [---] engagements


"Today we reported our first quarter [----] financial results and continued portfolio progress. We remain on track to deliver on all of our committed clinical milestones for [----]. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-first-quarter-2025-financial-results-and https://investors.metsera.com/news-releases/news-release-details/metsera-reports-first-quarter-2025-financial-results-and"  
[X Link](https://x.com/anyuser/status/1921884354562638291)  2025-05-12T11:05Z [---] followers, [---] engagements


"This morning we rang the @Nasdaq #OpeningBell in celebration of $MTSRs listing. It was a proud & symbolic moment for us highlighting the dedication of our team & our continued focus on addressing the burden of #obesity with trusted accessible medicines. Thank you to our exceptional team partners & supporters who helped make this day possible. https://twitter.com/i/web/status/1920203804890591350 https://twitter.com/i/web/status/1920203804890591350"  
[X Link](https://x.com/anyuser/status/1920203804890591350)  2025-05-07T19:47Z [---] followers, [---] engagements


"Metsera CEO Whit Bernard recently joined @bradloncar on @BiotechTVHQ to talk about what sets Metsera apart. Whit shares how were advancing a broad portfolio of therapies with potential best-in-class profiles to meet the future needs of a rapidly evolving weight loss treatment landscape. Watch the full conversation to learn more about how were accelerating the next generation of medicines for obesity and metabolic diseases: https://www.biotechtv.com/post/metsera-april-23-2025 https://www.biotechtv.com/post/metsera-april-23-2025"  
[X Link](https://x.com/anyuser/status/1915762138842382822)  2025-04-25T13:37Z [---] followers, [---] engagements


"This morning we announced our fourth quarter and full year [----] financial results and continued portfolio progress on our lead program MET-097i as well as our earlier-stage product candidates. For more details read the full press release here: https://investors.metsera.com/news-releases/news-release-details/metsera-reports-fourth-quarter-and-full-year-2024-financial https://investors.metsera.com/news-releases/news-release-details/metsera-reports-fourth-quarter-and-full-year-2024-financial"  
[X Link](https://x.com/anyuser/status/1904852957671174244)  2025-03-26T11:08Z [---] followers, [----] engagements


"Obesity impacts over a billion people worldwide leading to significant physical emotional and economic burdens on individuals and society. At Metsera our purpose is to reduce these burdens by developing trusted convenient and accessible medicines. This #WorldObesityDay we recognize the urgent need for scaled solutions for people with obesity. https://twitter.com/i/web/status/1896929549092364469 https://twitter.com/i/web/status/1896929549092364469"  
[X Link](https://x.com/anyuser/status/1896929549092364469)  2025-03-04T14:23Z [---] followers, [---] engagements


"RT @NasdaqExchange: 💓Focused on reducing the reducing the physical emotional and economic burdens of obesity. 🔬 @MetseraInc is a bioph"  
[X Link](https://x.com/anyuser/status/1885440275536814523)  2025-01-31T21:29Z [---] followers, [--] engagements


"💓Focused on reducing the reducing the physical emotional and economic burdens of obesity. 🔬 @MetseraInc is a biopharmaceutical company accelerating the next generation of obesity and metabolic disease medicines. 🥳So proud to be your exchange partner $MTSR Welcome to the #NasdaqListed family"  
[X Link](https://x.com/anyuser/status/1885421335171784789)  2025-01-31T20:14Z 773.5K followers, [----] engagements


"An excitingday for Metsera as we celebrate our official listing on @NasdaqExchange as $MTSR This marks an important step for the company and we extend thanks to our team and partners for their support in achieving this milestone"  
[X Link](https://x.com/anyuser/status/1885435968255131738)  2025-01-31T21:12Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing